Clinical factors to predict outcome following mogamulizumab in adult T-cell leukemia-lymphoma
書誌事項
- 公開日
- 2018-07-21
- 資源種別
- journal article
- 権利情報
-
- https://www.springer.com/tdm
- https://www.springer.com/tdm
- DOI
-
- 10.1007/s12185-018-2509-0
- 公開者
- Springer Science and Business Media LLC
この論文をさがす
説明
Adult T-cell leukemia-lymphoma (ATL) is a distinct T-cell malignancy caused by human T-cell leukemia virus type-1; the prognosis is very poor. Mogamulizumab (Moga), an antibody drug for CC chemokine receptor type 4, has been introduced for the treatment of ATL. However, the prognosis of relapsed or refractory ATL remains poor and the characteristics of patients who derive clinical benefit from treatment with Moga remain poorly understood. We analyzed the associations of clinical factors with the outcome after Moga treatment. Forty-five patients treated with Moga monotherapy were evaluated. The median age of the patients was 69 years, and 40% were female. The median overall survival (OS) time was 17.6 months and the 2-year OS rate was 43.2%. Number of prior therapies and response to prior therapy were predictive clinical features in univariate analysis for OS. Performance status, corrected serum calcium level, serum lactate dehydrogenase level, Japan Clinical Oncology Group-prognostic index (PI), and simplified ATL-PI at Moga treatment were also associated with the prognosis after Moga monotherapy. Improved understanding of the clinical factors predicting the prognosis after Moga may contribute to improved treatment strategies for ATL.
収録刊行物
-
- International Journal of Hematology
-
International Journal of Hematology 108 (5), 516-523, 2018-07-21
Springer Science and Business Media LLC
